Tamoxifen

Evidence Level: L5

Predicted Indications: 3

Tamoxifen

Pharmacist Assessment Report

Tamoxifen: From Female Breast Carcinoma to Mammary Paget Disease

One-Sentence Summary

Tamoxifen is an estrogen receptor-modulating drug, originally used to treat female breast carcinoma (including invasive ductal carcinoma and ductal adenocarcinoma of the breast). The TxGNN model predicts it may be effective for Mammary Paget Disease, but only 1 clinical trial (which does not test tamoxifen for this condition) and 10 publications (mostly case reports and case series) are available. The evidence for this specific prediction is weak, so this report also notes the stronger candidate among the ten predictions: breast carcinoma in situ.

Quick Overview

Item	Content
Original Indication	Female breast carcinoma, invasive ductal breast carcinoma, breast ductal adenocarcinoma (approved indication text is not available in the Canadian licence records)
Predicted New Indication	Mammary Paget disease
TxGNN Prediction Score	0.9969
Evidence Level	L5 (for the lead prediction)
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, tamoxifen is an estrogen receptor antagonist in breast tissue, and its efficacy in hormone-receptor-positive breast cancer is well established.

Mammary Paget disease is usually accompanied by an underlying ductal carcinoma in situ (DCIS) or invasive breast carcinoma, many of which are hormone-receptor-driven. Estrogen receptor blockade is therefore plausibly relevant. However, this is largely an extension of the existing breast cancer indication rather than true repurposing. No dedicated tamoxifen trial exists for Paget disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00002920	Phase 3	Completed	313	Medroxyprogesterone vs observation to prevent endometrial disorder in postmenopausal women taking tamoxifen (including those with Paget’s disease of the nipple). It does not test tamoxifen efficacy for Paget disease.

For the stronger candidate, breast carcinoma in situ, key trials include:

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01357772	Phase 3	Active, not recruiting	500	Placebo-controlled trial of low-dose tamoxifen (5 mg/day) in breast intraepithelial neoplasia (TAM-01)
NCT06982313	N/A	Completed	1545	Long-term follow-up and pooled analysis of low-dose tamoxifen in DCIS and high-risk lesions
NCT00072462	Phase 3	Completed	2980	IBIS-II DCIS: tamoxifen vs anastrozole after surgery for DCIS
NCT00053898	Phase 3	Completed	3104	Anastrozole vs tamoxifen in postmenopausal DCIS after lumpectomy with radiation
NCT00003857	Phase 3	Completed	636	Tamoxifen alone vs tamoxifen plus radiation in good-risk DCIS
NCT04046159	Phase 3	Unknown	810	Radiotherapy vs low-dose tamoxifen after breast-conserving surgery in low-risk ER-positive DCIS

Literature Evidence

For mammary Paget disease (lead prediction):

PMID	Year	Type	Journal	Key Findings
25759627	2014	Meta-analysis (cohort)	Breast Care	Local recurrence after mastectomy vs breast-conserving surgery for Paget’s disease; total recurrence 20-40%
1648987	1991	Review	Br J Surg	48 women with Paget’s disease of the nipple; tamoxifen used in one case
14965622	2001	Case report	Breast	Extensive nipple Paget’s disease; response achieved with tamoxifen, plus radiation therapy
34463889	2022	Case report	Invest New Drugs	Hormone receptor-positive metastatic extramammary Paget disease treated successfully with tamoxifen
16277886	2005	Case report	Clin Breast Cancer	Paget’s disease of the nipple as local recurrence after breast conservation
17319355	2006	Case series	Niger J Clin Pract	8 cases of nipple-areola Paget’s disease among 240 breast cancer patients

For breast carcinoma in situ (stronger candidate):

PMID	Year	Type	Journal	Key Findings
36917758	2023	RCT	J Clin Oncol	10-year follow-up of TAM-01: low-dose tamoxifen reduces recurrence in breast noninvasive neoplasia
30973790	2019	RCT	J Clin Oncol	Low-dose tamoxifen (5 mg/day) vs placebo to prevent local and contralateral recurrence
9747868	1998	RCT	J Natl Cancer Inst	NSABP P-1: tamoxifen for breast cancer prevention
25023044	2014	Systematic review	Breast	Cochrane meta-analysis of postoperative tamoxifen for DCIS

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
00851973	TEVA-TAMOXIFEN	Not specified	Not specified
00851965	TEVA-TAMOXIFEN	Not specified	Not specified
00812404	APO-TAMOX TAB 10MG	Tablet	Not specified
00812390	APO-TAMOX TAB 20MG	Tablet	Not specified

Cytotoxicity

Item	Content
Cytotoxicity Classification	Hormonal (endocrine) therapy, a selective estrogen receptor modulator; not a conventional cytotoxic agent
Myelosuppression Risk	Low. However, knowledge-graph data list thrombocytopenia and leukopenia as contraindication-related conditions, so blood counts should be monitored
Emetogenicity Classification	Low
Monitoring Items	CBC, liver function, calcium, gynaecological assessment (endometrial risk), thromboembolic symptoms
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Conditions flagged in contraindication data (from a knowledge graph, not label text): thrombocytopenia, hypercalcaemia, nephrocalcinosis, phosphorus metabolism disease, stroke and cerebrovascular disorders, cerebral infarction, pulmonary embolism, leukopenia, vision disorder, blindness.
Drug Interactions: 100 interactions are recorded. Major-level examples include bupropion, cimetidine, lorcaserin, dolasetron, eliglustat, cisapride, dexfenfluramine and fenfluramine. Moderate-level examples include famotidine, loperamide, aprepitant, dexamethasone, clarithromycin, granisetron and levofloxacin.
For the DCIS and ER-positive candidates, the evidence review also highlights endometrial cancer, venous thromboembolism and hot flashes as monitoring priorities.

Official package insert warnings and contraindications for Canada were not available. Please refer to the package insert for complete safety information.

Conclusion and Next Steps

Decision: Hold (for mammary Paget disease)

Rationale: The lead prediction rests on case reports, case series and recurrence studies, with no tamoxifen-specific trial. It is essentially an extension of the existing breast cancer indication. Of the ten predictions, only two have Phase 3 support (L1): breast carcinoma in situ (TAM-01, NSABP B-24 and IBIS-II) and ER-positive breast cancer. Both are guideline-supported or core indications that overlap with the approved scope, so they are closer to label extension or dose optimisation than novel repurposing, and both merit Proceed with Guardrails. Hormone-resistant breast cancer (L3) is a research question only. Basal-like breast cancer, the murine Ehrlich tumour, sebaceous breast carcinoma and vaginal rhabdomyosarcoma have little or no clinical support, and some conflict with the drug’s biology.

To proceed, the following is needed:

Canadian package insert warnings and contraindications (a blocking gap for safety screening)
Detailed mechanism of action data from DrugBank
Hormone receptor (ER) status confirmation of Paget disease and its underlying carcinoma, ideally in a prospective or registry study
For DCIS, a restriction to ER-positive disease, consideration of low-dose regimens, and monitoring for endometrial cancer and thromboembolism
A CYP2D6 and drug interaction review before use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.